Brief: Moberg Pharma Meets Primary Endpoint In The European Phase 3 Study

Moberg Pharma AB (publ)

25/06/2020 07:02

June 25 (Reuters) - Moberg Pharma AB (publ)  MBPH.ST :
    * MOBERG PHARMA MEETS PRIMARY ENDPOINT IN THE EUROPEAN PHASE
3
STUDY
    * ANNOUNCES THAT MOB-015 (TOPICAL TERBINAFINE) MET PRIMARY
ENDPOINT IN EUROPEAN PHASE 3 STUDY INCLUDING 452 ONYCHOMYCOSIS
PATIENTS, SHOWING NON-INFERIORITY VERSUS TOPICAL CICLOPIROX
    * MOB-015 WAS GENERALLY WELL TOLERATED

Source text for Eikon:  ID:nWkrc9TrHT 
Further company coverage:  MBPH.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587785110;))